News
Bevacizumab Study in Early-Stage Colon Cancer Misses Primary Endpoint
Bevacizumab Study in Early-Stage Colon Cancer Misses Primary Endpoint
L Scott-Zoeller
20090322
2009 Apr 22
OncologySTAT Editorial Team
Bevacizumab Study in Early-Stage Colon Cancer Misses Primary Endpoint
OncologySTAT Editorial Team. 2009 Apr 22, L Scott-Zoeller
Genentech, Inc., announced today that the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-08 study did not meet its primary endpoint of improved disease-free survival (DFS) with adjuvant use of bevacizumab (Avastin®) plus chemotherapy in patients with early-stage colon cancer. The announcement was made based on results from the final analysis of the NSABP C-08 study, a randomized multinational phase III study designed to evaluate the efficacy of adjuvant 5-fluorouracil, leucovorin,...
